| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACC1 |
| Uniprot No | Q00955 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 217-775aa |
| 氨基酸序列 | TGLVSVDDDIYQKGCCTSPEDGLQKAKRIGFPVMIKASEGGGGKGIRQVEREEDFIALYHQAANEIPGSPIFIMKLAGRARHLEVQLLADQYGTNISLFGRDCSVQRRHQKIIEEAPVTIAKAETFHEMEKAAVRLGKLVGYVSAGTVEYLYSHDDGKFYFLELNPRLQVEHPTTEMVSGVNLPAAQLQIAMGIPMHRISDIRTLYGMNPHSASEIDFEFKTQDATKKQRRPIPKGHCTACRITSEDPNDGFKPSGGTLHELNFRSSSNVWGYFSVGNNGNIHSFSDSQFGHIFAFGENRQASRKHMVVALKELSIRGDFRTTVEYLIKLLETEDFEDNTITTGWLDDLITHKMTAEKPDPTLAVICGAATKAFLASEEARHKYIESLQKGQVLSKDLLQTMFPVDFIHEGKRYKFTVAKSGNDRYTLFINGSKCDIILRQLSDGGLLIAIGGKSHTIYWKEEVAATRLSVDSMTTLLEVENDPTQLRTPSPGKLVKFLVENGEHIIKGQPYAEIEVMKMQMPLVSQENGIVQLLKQPGSTIVAGDIMAIMTLDDPSKV |
| 预测分子量 | 67.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACC1重组蛋白的模拟参考文献示例(内容为学术场景假设，建议通过学术数据库核实真实文献)：
---
1. **标题**：*Cloning and Functional Characterization of Recombinant Human ACC1 for Lipid Metabolism Studies*
**作者**：Chen, L., et al.
**摘要**：该研究成功在大肠杆菌系统中表达了具有活性的重组人ACC1蛋白，验证了其乙酰辅酶A羧化酶功能，并证明其在体外可调控脂肪酸合成通路。
2. **标题**：*Crystal Structure of ACC1 Recombinant Protein Reveals Novel Drug-Binding Sites*
**作者**：Kim, S., & Park, H.
**摘要**：通过解析ACC1重组蛋白的晶体结构，发现了与抑制剂结合的潜在位点，为开发代谢性疾病治疗药物提供了结构基础。
3. **标题**：*ACC1 Knockdown and Recombinant Protein Rescue in Hepatocellular Carcinoma Models*
**作者**：Wang, Y., et al.
**摘要**：利用重组ACC1蛋白回补实验，证实了ACC1在肝癌细胞脂质代谢异常中的关键作用，并揭示了其促癌机制。
4. **标题**：*Optimization of ACC1 Recombinant Expression in Insect Cells for High-Throughput Screening*
**作者**：Garcia, R., et al.
**摘要**：开发了基于杆状病毒-昆虫细胞系统的ACC1重组蛋白高效表达与纯化方案，适用于大规模药物筛选平台。
---
**注意**：以上内容为模拟生成，实际文献请通过 **PubMed/Google Scholar** 搜索关键词：*ACC1 recombinant protein*、*Acetyl-CoA carboxylase 1 expression* 等获取。如需具体文献指导，可提供研究背景进一步分析。
Acetyl-CoA carboxylase 1 (ACC1) is a biotin-dependent enzyme that catalyzes the ATP-dependent carboxylation of acetyl-CoA to produce malonyl-CoA, a critical rate-limiting step in *de novo* fatty acid synthesis. This cytosolic enzyme plays a central role in lipid metabolism, linking carbohydrate and lipid pathways by converting excess carbon into fatty acids for storage or membrane synthesis. Structurally, ACC1 contains three functional domains: a biotin carboxylase domain, a carboxyltransferase domain, and a biotin carboxyl carrier protein domain. Its activity is tightly regulated by phosphorylation (via AMPK) and allosteric effectors (e.g., citrate activation, palmitate inhibition), reflecting its metabolic importance.
Recombinant ACC1 proteins are widely used to study lipid metabolism dysregulation in metabolic syndromes, cancers, and metabolic liver diseases. They are typically produced in mammalian expression systems (e.g., HEK293 or insect cells) or *E. coli* (for truncated domains) with affinity tags (His-tag, GST) to facilitate purification. These recombinant tools enable *in vitro* studies of enzymatic kinetics, inhibitor screening (e.g., ND-630. TOFA), and structural analyses via cryo-EM or X-ray crystallography. Notably, ACC1's role in promoting tumor lipid synthesis has made it a therapeutic target in oncology, while its inhibition in metabolic tissues is explored for treating obesity and non-alcoholic fatty liver disease (NAFLD).
Pharmaceutical interest in ACC1 has intensified due to its dual role in fatty acid synthesis (cytosolic) and oxidation (via malonyl-CoA suppression of mitochondrial CPT1). Tissue-specific isoforms (ACC1 vs. mitochondrial ACC2) and regulatory complexity pose challenges but also opportunities for selective metabolic modulation. Current research leverages recombinant ACC1 to develop isoform-specific inhibitors and unravel post-translational modifications influencing metabolic diseases.
×
